Tango Therapeutics
TNGX • NASDAQ
Tango Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Malte Peters, with a market cap of $2.7B.
CEOMalte Peters
Next Earnings
Upcoming earnings announcement for Tango Therapeutics
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.32
Revenue Estimate
$635.9K
Earnings History
Past 12 earnings reports for Tango Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.29Est: -$0.32 | +9.4% | -Est: $500.4K | -100.0% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.14Est: -$0.04 | +450.0% | $53.8MEst: $42.2M | +27.5% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.35Est: -$0.35 | 0.0% | $3.2MEst: $6.5M | -51.1% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.36Est: -$0.35 | -2.9% | $5.4MEst: $6.7M | -19.9% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.35Est: -$0.34 | -2.9% | $4.1MEst: $8.0M | -48.7% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.27Est: -$0.37 | +27.0% | $11.6MEst: $7.8M | +48.6% | 10-Q |
| Aug 7, 2024 | Q2 2024 | -$0.24Est: -$0.34 | +29.4% | $19.9MEst: $7.4M | +167.9% | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.35Est: -$0.31 | -12.9% | $6.5MEst: $6.7M | -3.0% | 10-Q |
| Mar 18, 2024 | Q4 2023 | -$0.32Est: -$0.28 | -14.3% | $5.4MEst: $8.2M | -34.1% | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.23Est: -$0.34 | +32.4% | $10.7MEst: $7.3M | +46.6% | — |
| Aug 7, 2023 | Q2 2023 | -$0.23Est: -$0.34 | +32.4% | $14.6MEst: $7.0M | +110.0% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.32Est: -$0.35 | +8.6% | $5.8MEst: $6.7M | -14.1% | — |